Oculis Holding AG Investigation

Company: Oculis Holding AG

Ticker: (NASDAQ) OCS

See If You Qualify For Monetary Reward

Join the Oculis Holding AG Class Action Lawsuit

Investigation Details

Multiple SEC filings made prior to the stock collapse continued to present the OCS-01 DME program as progressing toward regulatory approval. A prospectus supplement filed on October 31, 2025 stated that topline results from the DIAMOND trials were "expected in the second quarter of 2026,” with a subsequent New Drug Applications (NDAs) submission to the U.S. FDA to begin in Q4 2026. A 6-K filed on October 6, 2025 described Oculis as being "in a strong position with multiple pivotal studies, targeting multi-billion-dollar markets" in connection with the DME program. The Company ultimately disclosed that the pivotal DIAMOND trials failed and announced it would abandon the FDA filing for DME entirely. Oculis stock fell over 23% on the announcement.

Frequently Asked Questions

How do I join the lawsuit against Oculis Holding AG (NASDAQ: OCS)?

Investors who purchased shares of Oculis Holding AG (NASDAQ: OCS) during the class period (March 15, 2024 - May 29, 2026) can join by submitting their transaction details through this case page.

Ensure your purchase falls within the class period
Provide basic transaction and loss details
Submit your information before the deadline

The lead plaintiff deadline for this case is To be determined, so investors should act quickly to protect their rights.

Who is eligible for the Oculis Holding AG lawsuit?

Anyone who bought shares of Oculis Holding AG (NASDAQ: OCS) during March 15, 2024 - May 29, 2026 and suffered financial losses may qualify.

What is the lead plaintiff deadline to join the Oculis Holding AG case?

The lead plaintiff deadline for the Oculis Holding AG lawsuit is To be determined. Investors should act quickly to avoid missing this deadline.

What is the class period for Oculis Holding AG?

The class period for Oculis Holding AG (NASDAQ: OCS) is March 15, 2024 - May 29, 2026, during which investors may have been affected by alleged misconduct.

Can I still join the Oculis Holding AG lawsuit if I sold my shares?

Yes. Investors who purchased Oculis Holding AG shares during March 15, 2024 - May 29, 2026 may still qualify, even if they sold their shares later.

How much compensation can I receive from the Oculis Holding AG lawsuit?

Compensation depends on the total losses and the final settlement. Eligible investors in the Oculis Holding AG case may receive a portion of the recovery.

Do I need to pay to participate in the Oculis Holding AG case?

No, most securities fraud cases involving Oculis Holding AG operate on a contingency basis, meaning there are no upfront costs unless there is a recovery.

Will I need to appear in court for the Oculis Holding AG lawsuit?

In most cases, investors do not need to appear in court. The legal team manages the Oculis Holding AG case on behalf of participants.

What documents are required for the Oculis Holding AG lawsuit?

To participate in the Oculis Holding AG lawsuit, investors may need to provide transaction records, purchase dates, number of shares, and loss details.

What happens after I submit my trade information for Oculis Holding AG?

After submission, your details for the Oculis Holding AG case will be reviewed, and you may be contacted regarding eligibility or next steps.

Is this legal advice for the Oculis Holding AG lawsuit?

No, this page provides information about the Oculis Holding AG case and does not constitute legal advice or create an attorney-client relationship.

Why should I act quickly on the Oculis Holding AG case?

The lead plaintiff deadline for the Oculis Holding AG lawsuit is To be determined. If you are an investor, you may have the opportunity to seek appointment as lead plaintiff or remain an absent class member.